US Clearance: Innovation Within the Constraints of "Substantial Equivalence" – A Case Study

The cornerstone of every 510(k) submission is the comparison to a so-called "predicate device." Differences are generally permissible, provided that "substantial equivalence" can be demonstrated. The principle: the manufacturer must show that their own product is substantially equivalent to an already-cleared product – the predicate device.

Where this is not feasible due to differences in technology or indication/intended purpose, pathways such as a De Novo submission are available. However, a De Novo submission costs approximately six times as much as a 510(k), and the estimated review time is nearly twice as long – a route that is time-consuming, resource-intensive, and often not economically viable, particularly for smaller product categories.

But how can an innovative product with new features be considered "substantially equivalent" to another product? The story of the ArgoCap® by Ovesco Endoscopy demonstrates that, with the right strategy, innovation can reach the market through the 510(k) pathway.

ArgoCap®

The ArgoCap® is an endoscopic cap attachment for argon plasma coagulation (APC) in the gastrointestinal tract. Unlike conventional endoscopic caps, the ArgoCap® features an integrated guide for the APC probe. The probe is routed outside the endoscope shaft, angled, and fixed in a defined position. This enables focused treatment under direct visual control, protects the probe from tissue contact, and improves endoscopic handling. At the same time, the working channel of the endoscope remains free for additional instruments.

The ArgoCap® is already well established in Europe for the treatment of Barrett's esophagus, gastric antral vascular ectasia (GAVE) syndrome, and angiodysplasias.

No Predicate, No 510(k)?

The manufacturer, Ovesco Endoscopy, sought to pursue the 510(k) pathway. However, while a number of simple endoscopic caps exist, there was no cleared predicate device featuring an APC probe guide. The available endoscopic caps had been cleared for other purposes – for visualization in anatomically challenging conditions, for endoscopic mucosal resection, and for maintaining optimal depth of view.

The Strategy: Terminology as a Regulatory Lever

An extensive De Novo process or technological compromises were not an option for the manufacturer. The solution lay in a precise analysis of the intended purpose. The first step was to determine what intent and marketing positioning were associated with the product: Which claims could not be relinquished? How willing was the company to align with a predicate device in order to pursue the 510(k) pathway? The goal was to derive a shared underlying intended purpose from existing indication language, and to formulate the device's own indication in a way that left the intended purpose intact.

The identified predicate device – a conventional endoscopic cap – had two central elements in its FDA clearance: first, gastrointestinal mucosal resection; second, maintaining adequate depth of the endoscope's field of view. The second point was the key. Both products – the conventional cap and the ArgoCap® – serve the function of distance and visual control during endoscopic procedures.

Rather than formulating an entirely new intended purpose, the existing one was expanded minimally but deliberately. The intended purpose of the ArgoCap® read: gastrointestinal endoscopic mucosal resection and coagulation, as well as maintaining adequate depth of the endoscope's field of view. Three words – "and coagulation" – made the difference. The core function remained identical, coagulation was integrated as an additional area of application, and substantial equivalence remained arguable.

Pre-Submission Consultation with the FDA

Before investing time and resources into a full 510(k) submission, a Q-Submission was filed with the FDA. The central question was: Is this pathway viable? Because despite all available examples, experience, and guidance documents, demonstrating "substantial equivalence" in the presence of differences in indication and technology always involves a degree of subjective interpretation and application of requirements.

In this case, we proactively sought dialogue with the FDA through a Q-Submission. Crucially: do not ask "am I allowed to do it this way?", but rather present the reasoning developed beforehand in a well-substantiated manner. The outcome was a set of concrete proposals for bench test scenarios that the FDA deemed necessary in view of the identified differences.

In this case, we proactively sought dialogue with the FDA through a Q-Submission. Crucially: do not ask "am I allowed to do it this way?", but rather present the reasoning developed beforehand in a well-substantiated manner. The outcome was a set of concrete proposals for bench test scenarios that the FDA deemed necessary in view of the identified differences.

The Outcome: 510(k) Clearance

The Q-Submission allowed the bench test battery for the product to be rounded out and completed. The subsequent 510(k) submission was able to reference the Q-Submission directly, demonstrate that the FDA's feedback had been consistently implemented, and ultimately led to a successful clearance.

Conclusion: Innovation Requires Strategy

This case study demonstrates that the requirement for "substantial equivalence" does not mean that products must be identical. Innovative features can be incorporated as long as the core function remains comparable. How a product is described can make the difference between a viable and a non-viable regulatory pathway. Sometimes, all it takes is the right two words.

Pre-submission consultation with the FDA requires time and money – but significantly less than a rejected 510(k) submission or an unnecessary De Novo process. Targeted performance data can substantiate an expanded intended purpose and are generally faster and more cost-effective than a De Novo clearance.